Latest Biotech News

GSK agreed to acquire 35Pharma for $950 million in cash, gaining HS235 — a protein‑based activin receptor signalling inhibitor positioned for pulmonary hypertension indications. HS235 completed...

A Senate Aging Committee hearing and patient‑advocate protests this week put FDA rare‑disease review practices under scrutiny, as witnesses and patient groups described inconsistent regulatory...

Two reports describe technology advances aimed at overcoming key barriers to CAR‑T efficacy in solid tumors. Researchers unveiled ultra‑sensitive CAR T cells engineered to detect low‑density...

A tumor‑informed circulating tumor DNA (ctDNA) assay published in Nature Communications demonstrated strong prognostic power for patients with anal squamous cell carcinoma. The study showed that a...

Two hardware vendors revealed commercial sequencing advances at AGBT. Roche disclosed the Axelios 1 platform with a list price for consumables that equates to a $150 human genome at 30X in its...

Two delivery‑focused RNA plays signaled momentum in RNA therapeutics beyond the liver. City Therapeutics, led by RNAi veteran John Maraganore, is developing cleavage‑inducing tiny guide RNAs...

Novo Nordisk announced a research-and-license agreement with Vivtex to develop orally delivered peptide and protein therapeutics targeting obesity, diabetes and related metabolic conditions....

GSK agreed to acquire 35Pharma for $950 million in cash, obtaining HS235, a protein‑based activin‑signalling inhibitor being positioned for pulmonary hypertension (PH). GSK stated the deal will...

Japanese conglomerate Asahi Kasei agreed an all‑cash acquisition of German antiviral specialist Aicuris for roughly €780 million (about $920 million). The purchase brings marketed product Prevymis...

Ultima Genomics unveiled the UG200 sequencing family and Solaris 2.0 workflows, positioning the company for high‑throughput, lower‑cost human genome production. The UG200 line offers flexible...

Roche disclosed more details on its Axelios 1 sequencing platform at AGBT, including a claimed consumable cost equating to $150 per 30X human genome in duplex mode. Roche provided workflow and...

Illumina introduced TruPath long‑read genome capabilities at the AGBT meeting, positioning the product as a competitor to PacBio’s native long reads and to other high‑throughput platforms in...

A Senate Aging Committee hearing and related advocacy sessions put the FDA’s rare‑disease review process under scrutiny, with patient groups and clinicians pressing for consistency and clearer...

Eli Lilly reported head‑to‑head clinical trial results showing its oral GLP‑1 candidate achieved larger reductions in blood glucose and body weight versus Novo Nordisk’s oral semaglutide...

Researchers published a tumor‑informed circulating tumor DNA (ctDNA) assay that predicted recurrence and survival outcomes in anal squamous cell carcinoma (ASCC). The Nature Communications study...

Lex Diagnostics commenced commercialization of Velo, a point‑of‑care molecular diagnostic platform cleared by the FDA (510(k)) with a CLIA waiver for a flu/COVID assay. The Velo delivers...

Ultima Genomics unveiled its UG200 instrument family and Solaris 2.0 workflows, announcing higher throughput, reduced footprint and a 1‑day library‑to‑data turnaround aimed at population‑scale...

SPT Labtech announced a strategic collaboration with Illumina to develop an automated sample‑preparation platform for the MiSeq i100 benchtop sequencer, aiming to bring standardized NGS workflows...

Lex Diagnostics has started commercialization of Velo, an FDA 510(k)‑cleared and CLIA‑waived cartridge‑based qPCR system that yields sample‑to‑answer results in roughly 10 minutes for flu and...

Novo Nordisk entered a strategic collaboration with Vivtex to develop oral formulations of peptide and protein therapeutics, a deal that could total up to $2.1 billion including milestones and...